Rashmi Rajashekaraiah

Dr. Rashmi Rajashekaraiah


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
RRRashmi Rajashekaraiah
Rashmi Rajashekaraiah
PKP. Ravi Kumar
P. Ravi Kumar
NPN. Prakash
N. Prakash
GRG. Srinivasa Rao
G. Srinivasa Rao
VDV. Rama Devi
V. Rama Devi
PGPrem Kumar Govindappa
Prem Kumar Govindappa

27 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MYMuralidhar Yegireddy
Muralidhar Yegireddy
PNPrakash Nadoor
Prakash Nadoor
SRSuguna Rao
Suguna Rao
PHPavithra Balekatte Hanumanthu
Pavithra Balekatte Hanumanthu
RRRashmi Rajashekaraiah
Rashmi Rajashekaraiah
SUSunilchandra Ubaradka
Sunilchandra Ubaradka
Meloxicam (MLX) is currently used in the therapeutic management of both acute and chronic inflammatory disorders such as pain, injuries, osteoarthritis, and rheumatoid arthritis in both humans and animals. Gastrointestinal toxicity and occasional renal toxicity were observed in patients taking it for a long-term period. Meloxicam’s late attainment of peak plasma concentration results in a slow onset of action. The goal of the current study was to prepare and characterize chitosan encapsulated meloxicam nanoparticles (CEMNPs) with high bioavailability and less gastro intestinal toxicity in order to prevent such issues. The size of the prepared CEMNPs was approximately 110–220 nm with a zetapotential of +39.9 mV and polydispersity index of 0.268, suggesting that they were uniformly dispersed nanoparticles. The FTIR and UV-Vis spectroscopy have confirmed the presence of MLX in the prepared CEMNPs. The pharmacokinetics have been studied with three groups of male Wistar rats receiving either of the treatments, viz., 4 mg·kg−1 of MLX and 1 or 4 mg·kg−1 of CEMNPs. Plasma samples were collected until 48 h post administration, and concentrations of MLX were quantified by using reverse (C18) phase HPLC. Non-compartmental analysis was applied to determine pharmacokinetic variables. Upon oral administration, the maximum concentration (Cmax) was reached in 4 h for CEMNPs and 6 h for MLX. The mean area under the plasma MLX concentration-time curve from ‘zero’ to infinity (AUC0–∞), half-life (t1/2β), and mean resident time (MRT) of 1 mg·kg−1 of CEMNPs was 1.4-, 2-, and 1.8-fold greater than 4 mg·kg−1 of MLX. The prepared CEMNPs demonstrated quicker absorption and prolonged release along with a significant improvement in the bioavailability of MLX, paving a prospective path for the development of drugs with enhanced bioavailability with less side effects.

30 July 2021 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
BGB. Rudresh Gowda
B. Rudresh Gowda
PNPrakash Nadoor
Prakash Nadoor
CSC. R. Santhosh
C. R. Santhosh
BPB. H. Pavithra
B. H. Pavithra
RRRashmi Rajashekaraiah
Rashmi Rajashekaraiah
MYMuralidhar Yegireddy
Muralidhar Yegireddy

10 March 2020 in International Journal of Current Microbiology and Applied Sciences
Verified
Journal Article
Open access
MKMedha Karnik
Medha Karnik
AKAnjan Kumar
Anjan Kumar
MMM. Manjula
M. Manjula
HLH. D. Lohitha
H. D. Lohitha
RNR. Narendra
R. Narendra
MSM. L. Satyanaryana
M. L. Satyanaryana
International Journal of Current Microbiology and Applied Sciences ISSN:2319-7692(Print), ISSN:2319-7706(Online) is a multidisciplinary peer-reviewed journal with reputable academics and experts as members of its Editorial Board. The Current Microbiology aims to publish all the latest and outstanding research articles. Review and letters in all areas of major importance to techniques of microbiology and applied research with publishes high quality of review and research articles on novel aspects of Microbiology including Environmental, Food, Agricultural, Medical, Pharmaceutical, Veterinary, Soil, Water and Biodeterioration.